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Abstract 
 
A HPLC-MS/MS method, which was suitable to be used in withdrawal time studies, was validated for the 
determination of fosfomycin in swine muscle, liver, kidney and skin-fat. Therefore, the withdrawal time of 
fosfomycin in swines, considering a MRL of 0.5 µg/mL was studied. Forty-eight pigs were assigned to two 
groups; in group one, fosfomycin was orally administered daily with 30 mg⁄kg bw and to the other group a dose 
of 15 mg⁄kg bw of the antibiotic was intramuscularly administered. Pigs were slaughtered 24, 48, 72 and 96 
hours later of oral treatment withdrawn and post intramuscular treatment. The longer WDT was 2.95 days for 
the PO administration and 1.73 days for the IM administration; therefore, WDTs of 3 days and 2 days, 
respectively, could be assigned as a precautionary principle for public health, without a significant economic 
impact for the swine producer.  
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Introduction 
Fosfomycin (cis-1, 2-epoxyphosphonic acid) 
(Figure 1) is a broad-spectrum bactericidal 
antibiotic, not structurally related to other classes of 
antimicrobial agents. It acts inside the bacterial 
cytoplasm
 
(Popovic et al., 2009) and its mechanism 
of action is based in the inhibition of cell wall and 
early murein/peptidoglycan synthesis in 
proliferating bacteria (Kahan et al., 1974). 
Fosfomycin inhibits an initial peptidoglycan 
synthesis step, triggered by uridine diphosphate N-
acetyl-glucosamine-enol-pyruvyl-transferase and its 
co-enzyme phosphonole-pyruvate (Kahan et al., 
1974; Lin, 1976; Popovic et al., 2009). It has 
bactericidal activity against Gram positive and 
Gram negative bacteria
 
(Gobernado, 2003). 
Therefore, when compared with other antibiotics, 
the in vitro fosfomycin activity has a broader 
spectrum of action than penicillins and semi-
synthetic cephalosporins (Mata et al., 1977). On the 
other hand, it appears to be little cross resistance 
with other antimicrobial agents, possibly due to its 
chemical structure and action site are different from 
other agents (Gobernado, 2003; Reeves, 1994).
 
 
 
Fig. 1: Chemical structure of fosfomycin. 
 
The use of fosfomycin in animals and humans 
has been suggested due to its low toxicity and 
potential efficacy (Gallego et al., 1974). It is well 
tolerated, with a low incidence of adverse events 
and rapid bactericidal effect (Patel, 1997). 
Fosfomycin forms salts easily due to its acidic 
nature. Orally, it is used in its calcium salt form 
(Figure 2), and intravenously and intramuscularly, 
as the more water-soluble disodium salt (Figure 3). 
Fosfomycin-tromethamine salt is highly hydro-
soluble and has a good oral bioavailability in 
humans (Patel et al., 1997; Borsa et al., 1988; 
Popovic et al., 2009). Fosfomycin is also widely 
used in animal production, especially in poultry and 
pig production, due to its rapid effect, good 
tolerance and absence of side effects (Aramayona et 
al., 1997; Carramiñana et al, 2004). Particularly in 
swine’s, this antibiotic is used for the treatment of 
infectious diseases caused by Haemophilus 
parasuis, Streptococcus suis, Pasteurella multocida, 
Bordetella bronchiseptica, Staphylococcus hyicus 
and E. coli), associated with stress and different 
viral infections (Martineau, 1997). 
 
 
Fig. 2: Chemical structure of calcium fosfomycin. 
 
Fig. 3: Chemical structure of disodium fosfomycin. 
 
Fosfomycin pharmacokinetic has been 
extensively studied in humans
 
(Dámaso et al., 1990; 
Falagas et al., 2008; Gallego et al., 1971; Grassi, 
1990; Kirby, 1977; Mensa et al., 1994; Segre et al., 
1987; Simon et al., 1987; Vargas et al 1987), broiler 
chickens
 
(Aramayona et al., 1997, Soraci et al., 
2011), rabbits
 
(Fernández Lastra et al., 1986; 1987), 
cows
 
(Sumano et al., 2007), horses
 
(Zozaya et al., 
2008), dogs
 
(Gutierrez et al., 2008) and pigs
 
(Soraci 
et al, 2010; Pérez et al., 2013). Likewise, different 
analytical methods for determination of fosfomycin 
in biological matrices have been described in the 
literature (Pianetti et al., 1997; Dios-Viéitez et al., 
1996; Yu-Ling Hu et al., 1999; Hernandez et al., 
2001; Loste et al., 2002; Tzanavaras et al., 2002; 
Petsch et al., 2005). Most of them are time 
consuming and include a derivatization step for the 
analysis. Currently, HPLC MS/MS is the method of 
choice for xenobiotics residues determination. For 
fosfomycin, this method has the advantage that 
derivatization is not needed, becoming a much 
easier, less time consuming, and highly specific 
methodology at the same time (Li Li et al, 2007; 
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Dieguez et al, 2011; Soraci et al, 2011; Pérez et al., 
2011). However, when working in HPLC-MS/MS 
with biological matrices, care must be taken to 
avoid interferences which are prone to alter signal 
by ion suppression/enhancement mechanisms. 
The administration of veterinary drugs to food-
producing animals without an adequate withdrawal 
time (WDT) may lead to violative concentrations of 
residues in foods intended for human consumption. 
These residues represent a risk to public health, 
including stimulation of bacterial resistance, 
alterations on intestinal microflora and 
hypersensitivity reactions. Therefore, to ensure the 
delivery of safe animal products to consumers, the 
withdrawal time of drugs must be respected. Thus, 
with the aim of minimizing the risk for human 
health represented by residues in food products, 
MRLs for many drugs have been established by 
regulatory agencies of different countries. However, 
the European Agency for the Evaluation of 
Medicinal Products (EMEA) and the European 
Commission have not established the MRLs for 
fosfomycin. The Japan Food Chemical Research 
Foundation has established MRLs of 0.5 µg/mL for 
cattle muscle, liver, kidney and fat and a MRL of 
0.05 µg/mL for milk. No MRLs has been 
established for pig tissues by any regulatory 
agencies. 
In the extra vascular administration of a drug, 
the pharmaceutical formulation may condition the 
rate of absorption and, consequently, the final 
elimination phase. According to this, a formulation 
may require a longer WDT when the drug is slowly 
depleted from tissues. Otherwise, a shorter WDT 
can be used when faster depletion is adequately 
proven. Consequently, the administration of one or 
another formulation of the same drug leads to 
violative concentrations of residues if individual 
WDTs are not considered. Although there are 
different pharmaceutical formulations of 
fosfomycin, only the calcium salt is used in pigs for 
oral administration, while the more water-soluble 
disodium salt is used intramuscularly
 
(Soraci et al., 
2010; 2011). Nevertheless, and considering that 
fosfomycin is an antibiotic widely used for pig 
production, WDT in swine tissues has not been 
investigated. 
On a previous work we have studied 
fosfomycin residual concentrations in chicken 
muscle, liver and kidney by HPLC MS/MS (Pérez 
et al., 2011). In the present study, this simple, rapid 
and highly selective HPLC-MS/MS method was 
validated to determine fosfomycin in swine tissues 
(muscle, liver, kidney and skin-fat). This study was 
also aimed to determine WDTs of calcium 
fosfomycin in pigs after an oral treatment and of 
disodium fosfomycin after intramuscular 
administration. For this purpose, the only known 
fosfomycin MRL (0.5 µg/mL), established by 
Japan, was considered (Japan Food Chemical 
Research Foundation).   
Materials and Methods 
This work was performed at the Laboratory of 
Toxicology, Veterinary Research Center of Tandil 
(CIVETAN-CONICET) and the experimental farm 
of the Faculty of Veterinary Sciences, UNICEN, 
Tandil, Buenos Aires, Argentina. 
Animals 
For method validation, five healthy, 145-150 
day-old pigs were used. Animals received an 
antibiotic-free diet and water ad libitum. After 
euthanasia, tissue samples were collected. Organs 
were weighted and 1:2 part of methanol was added. 
Then, tissues were processed by a hand blender and 
stored at -20 ºC until analysis.  
For residue analysis and withdrawal time 
calculation, forty-eight healthy 145-150 day-old 
pigs, were used. One week before experimentation 
(acclimation period), no clinical signs of disease 
were apparent. Food (the ration was formulated 
according to breed standard requirements) and no 
medicated water were supplied ad libitum. 
Experimental animal’s conditions were in 
agreement with the Animal Welfare Guidelines 
approved by the Bioethics Committee of the Faculty 
of Veterinary Sciences, UNICEN, Tandil, Argentina 
and the recommendations of the European Council 
Directive 2007⁄43. Pigs were sacrificed under the 
Animal Welfare Rules of the European Council 
Directive 93 ⁄ 119 ⁄ CE 1993.  
Pigs were weighed and divided randomly into 
two experimental groups of twenty four animals (A 
and B groups). The A group (24 pigs) was treated 
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individually with 30 mg⁄ kg bw of calcium 
fosfomycin (98.9% of purity; Bedson Laboratory, 
Pilar, Buenos Aires, Argentina) orally administrated 
once daily for five consecutive days (every 
morning, between 7 and 8 a.m.). The drug was 
weighed, diluted in water and administrated using a 
plastic gastric catheter to assure the complete 
ingestion of the dose. For intramuscular assay, (B 
group, 24 animals), disodium fosfomycin (98.9% of 
purity, Bedson Laboratory, Pilar, Argentina) was 
diluted in sterile water and intramuscularly 
administered, at 15 mg/kg. bw.  
Reagents and chemicals 
Fosfomycin calcium and disodium salts 
(analytical standard, STD), purchased from Sigma 
(St. Louis, USA), were used. HPLC grade 
acetonitrile, isopropanol and methanol were from 
JT Baker (Deventer, Holland). Ultra purified de-
ionized water was obtained using a water 
purification devise (Pure Lab UHQ from ELGA 
[Lane End, UK]). Silica Gel 60 (0.040-0.063 mm.) 
was from Merck (New Jersey, USA). Stock solution 
of fosfomycin was prepared by dissolving 10.0 mg 
of drug in 25 mL of purified water.   
Instruments HPLC MS/MS system  
The HPLC-MS/MS system was from Thermo 
Electron Corporation (San Jose, CA, USA), 
consisting of a Finnigan Surveyor auto sampler and 
a Finnigan Surveyor MS quaternary pump. The 
detector was a Thermo Quantum Discovery Max 
triple quadrupole mass spectrometer, equipped with 
an ESI source. Nitrogen used as nebulizer and 
sheath gas was obtained through a nitrogen 
generator from Peak Scientific Ltd. (Inchinnan, 
Scotland). Data processing was done using Xcalibur 
software, also from Thermo.  
Mass Spectrometer conditions 
The mass spectrometer was operated in 
negative ionization mode. The tuning parameters 
were optimized with 10 µg/mL individual aqueous 
solutions of fosfomycin directly infused in the ion 
source by means of a syringe pump at 10 µl/min, 
with influence of mobile phase delivered from the 
LC pump through a T connection to give the 
corresponding chromatographic flow rate. The 
spray voltage was set at -3800 eV, the capillary 
temperature was 350 ºC, and argon 99.99% purity 
was used for collision induced dissociation (CID) at 
1.6mTorr in the collision cell. Source CID energy 
was set at -8eV. Fosfomycin detection and 
quantification were achieved by single reaction 
monitoring of transitions m/z 137 79 with an 
optimized collision energy of 25. 
Chromatographic conditions 
Separation was achieved on a Phenomenex CN 
(cyano) stationary phase, 75 mm x 4.6 i.d., 5µm-
column. The mobile phase consisted on 
acetonitrile:water (20:80), working in isocratic 
mode, at a flow rate of 100 µl/min. The column was 
maintained at 30 ºC, while the samples in the auto 
sampler were at 10 ºC. Sample injection volume 
was 20µl and chromatographic run time was 10 
min. 
Standard solutions preparation 
Quality control samples (QC) 
Fosfomycin solutions to fortify drug free 
tissues before extraction were prepared daily, by 
diluting adequate volumes of stock solution in 
water. Fifty µl of each solution were thoroughly 
mixed with 1 g of tissue, to obtain effective 
fosfomycin concentrations of 0.1, 0.5 and 1 µg/mL. 
Calibration solutions 
Drug free extracts were spiked with 100 µl 
fosfomycin working solution at different levels just 
before injection into HPLC-MS/MS system, to 
obtain concentrations corresponding to 100% 
extraction over the range of 0.1 to 4 µg/mL.  
Sample extraction  
One gram of tissue was placed in a glass mortar 
containing four grams of silica gel and mortared 
until the sample was completely dispersed into the 
silica. Columns were assembled in 20-mL syringes, 
placing a Whatman GF/B filter on the bottom, 
followed by a dispersion of silica gel with the 
tissues. Another Whatman GF/B filter was placed 
above. Columns were pressed with a piston. Each 
column was placed in a vacuum chamber, where 
different volumes of solvents were applied to wash 
and elute the sample. Clean up began with 6 mL of 
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acetonitrile. Pressure was kept constant and leakage 
was uniform in all columns. Then, 5 mL of 
isopropanol were applied. The next step was the 
addition of 6 mL of methanol. All the solvents were 
collected in glass tubes and discarded. Properly 
labeled clean glass tubes were placed in the vacuum 
chamber. Nine mL of methanol-water (2:1) were 
added and eluted. The 9 mL-eluate was filtered in 
syringes containing activated carbon and 1 mL 
aliquots were filtered with 0.22 µ nylon filters, 
placed in vials and analyzed by HPLC MS-MS. 
Method validation 
Validation parameters, as well as their 
acceptance range, were in accordance with 
international guidelines (U. S. Department of Health 
and Human Services, FDA, CDER, CVM, 2001; 
European Commission Decision, 2002). 
Quantification was achieved by calculating 
fosfomycin area as the assay response.  
Calibration curves were prepared in 
quintuplicates, and assayed within one week, in 
order to assess Linearity. Least square linear 
regression was used for curve fitting. 
QC samples fortified at three levels were 
processed in triplicates on four separate days, in 
order to assess Accuracy and Precision of the 
method. The accuracy was expressed as relative 
error (RE) and it was required to be ±15% (except 
for the limit of detection that can reach up to 20%). 
Within-day precision (repeatability) was calculated 
by the mean coefficient of variation (CV), which 
was required to be less than 15% for all 
concentrations (except for the limit of detection 
where it can reach up to 20%).  
Lower limit of quantification (LOQ) was 
defined as the lowest concentration at which both 
precision and accuracy were less than or equal to 
20%, and it was obtained by analyzing fortified 
tissues at the lower level of the calibration curve, in 
5 replicates on three different days. 
Recovery of fosfomycin following extraction 
was calculated by comparing the fosfomycin mean 
peak area of QC samples with the values obtained 
for post-extraction spiked samples, which 
represented 100% recovery.  
Selectivity was determined by analyzing tissues 
from 6 healthy pigs, which had never received 
antimicrobial treatment, each coming from different 
farms. 
Decision limit (CCα) and Detection capability 
(CCβ) 
The decision limit (CCα) is defined as the limit 
above which it can be concluded with an error of 
probability of α, that a sample contains the analyte. 
The detection capability (CCβ) is defined as the 
lowest concentration of analyte at which the method 
is able to detect and quantify contaminated samples 
with a statistical certainty of 1-β (European 
Commission Decision, 2002).  
Matrix effects evaluation 
For matrix effects evaluation, two types of 
studies were conducted, as described. On one hand, 
peak area ratios obtained with fosfomycin aqueous 
solutions, at three concentration levels within the 
linear range, were compared with those obtained 
with extracted blank tissues, spiked at the same 
concentration, just before injection. On the other 
hand, each blank tissue extract was injected at the 
same time a fosfomycin aqueous solution was being 
directly infused into the ion source. Matrix effects 
were observed by enhancement or reduction of the 
signal at certain regions of the chromatogram. 
Residues analysis and withdrawal time 
calculation 
Residues analysis 
Oral Assay 
Testing and Sampling: On the fifth day of trial 
fosfomycin dosage was discontinued. Twenty-four 
h later, the first group of animals (six pigs) was 
sacrificed. The next day, the second group of 
animals was euthanized (six pigs). After 72 h of 
drug dosage suspension, other six pigs were 
sacrificed. The last group of six animals was 
euthanized 96 h after administration.  
Samples: Samples were collected in plastic 
bags (Ziploc ® type), quickly cooled and stored at-
80 º C until assayed. A total of 96 tissue samples 
were obtained (twenty four samples by tissue; six 
samples by tissue each of the four days of 
slaughtering). 
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Intramuscular Assay 
Testing and Sampling: Experimental animals 
were intramuscularly dosed. Twenty four h after 
dosage, the first group of animals was sacrificed. 
The next day, six more pigs were sacrificed. 
Seventy-two h post-administration, other six 
animals were slaughtered. The remaining group of 
six animals was euthanized after 96 h of 
intramuscular assay beginning.  
Samples: Samples were taken from muscle, 
liver, kidneys and skin-fat of each animal and they 
were collected in plastic bags (Ziploc ® type), 
quickly cooled and stored at -80 º C until assayed. A 
total of 96 tissue samples were obtained (twenty 
four samples by tissue; six samples by tissue each 
of the four days of slaughtering). 
Fosfomycin determination in swine tissues was 
based on the method previously mentioned. Data 
processing was performed by Xcalibur software 
(Thermo Corporation). Quantification was achieved 
by calculating fosfomycin area as the assay 
response. The 192 analyzed samples were: 
Muscle: Forty eight samples, (twenty-four oral 
samples and twenty-four intramuscular samples, all 
analyzed by duplicate). 
Liver: Forty-eight samples (twenty-four oral 
samples and twenty-four intramuscular samples, all 
analyzed by duplicate).  
Kidney: Forty-eight samples (twenty-four oral 
samples and twenty-four intramuscular samples, all 
analyzed by duplicate). 
Skin-fat: Forty-eight samples (twenty-four oral 
samples and twenty-four intramuscular samples, all 
analyzed by duplicate). 
Determination of withdrawal times 
The fosfomycin area at each sampling time was 
considered for the determination of WDTs in 
muscle, liver, kidney and skin-fat, adopting the 
European Agency for the Evaluation of Medicinal 
Products recommendations
 
(EMEA, 1995). The 
WDTs were estimated from the linear regression 
analysis of log-transformed tissue concentration and 
was determined at the time when the 95% upper 
one-sided tolerance limit was below the MRL with 
95% confidence. For this purpose, the statistical 
program WTM 1.4 was used. 
Results and Discussion 
Method development 
Optimization of mass spectrometer conditions 
High spectrometric response was observed 
when working in ESI negative ion mode for 
fosfomycin STD. The predominant ion obtained 
was de-protonated fosfomycin, which m/z value 
was 137, in the Q1 (or Q3) full scan spectra. 
The direct infusion from syringe pump of 
independent solutions of fosfomycin STD, allowed 
the observation of changes in response as well as in 
MS parameters. Thus, the most suitable conditions 
of the ion source in order to obtain the highest 
signal from parent ions were found to be the 
following: Spray voltage: -3800eV; Spray 
temperature: 350ºC; Source CID energy: -8eV and 
Sheath gas pressure: 1.5. 
Using the same technique, collision pressure 
and collision energy in Q2 was evaluated. For 
fosfomycin, a predominant fragment ion of m/z 79 
was formed when collision pressure was 1.6 and 
collision energy -25 eV. The intensity of parent ions 
showed a more than 80% reduction. 
Optimization of chromatographic system 
The use of a cyano (CN) stationary phase 
greatly improved the retention, when compared to a 
C18.  
Method validation 
Validation parameters 
Selectivity 
No signal above the base line at fosfomycin 
retention time was observed in tissues from 
chickens to which antimicrobials had not been 
administered. Figures 4a to 7a show typical blank 
chromatograms of muscle, liver, kidney and skin-
fat, compared with spiked tissue samples (Figures 
4b to 7b). 
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Fig. 4a: Blank muscle. 
 
 
 
Fig. 4b: 0.1 µg/mL spiked muscle. 
 
 
 
Fig. 5a: Blank liver. 
 
 
Fig. 5b: 0.1 µg/mL spiked liver. 
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Fig. 6a: Blank kidney. 
 
 
 
Fig. 6b:  0.1 µg/mL spiked kidney. 
 
 
Fig. 7a: Blank skin-fat. 
 
 
Fig. 7b:  0.1 µg/mL spiked skin-fat. 
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Linearity 
A typical linear regression curve was 
constructed over the range 0.01 to 0.4 µg/mL 
(representing 0.1 to 4 µg/mL of swine muscle, liver, 
kidney or skin fat). Good linearity was obtained 
within the concentration range, being r
2
 coefficient 
above 0.995 for all matrix replicates.  
Accuracy and Precision 
Accuracy and precision were evaluated for 
spiked samples at different levels. Accuracy, 
expressed as RE, was 4.00%-9.00% for muscle, 
3.00%-4.00% for liver, 2.00%-3.00% for kidney 
and 2.00%-3.00% for skin-fat. Repeatability (within 
day precision) was less than 13 % for all studied 
concentrations, except for the 0.1 µg/mL spiked 
samples of skin-fat, which was 17.70 %, a value 
that was accepted because it was our detection limit 
(CV<20%).  
Extraction Recovery 
Drug recovery was tested for swine tissue 
samples spiked at different levels. Mean extraction 
recoveries were between 82.56 to 111.48 % for 
muscle, 90.85 to 106.93 % for liver, 99.99 to 120 % 
for kidney and 95.04 to 120 % for skin-fat. 
Decision limit (CCα) and detection capability 
(CCβ) 
CCα and CCβ values were calculated using the 
intercept (value of the signal, y, where the 
concentration, x, is equal to zero) and the standard 
error of the intercept (SEI). CCα is the 
concentration corresponding to the intercept + 
2.33×the SEI. CCβ is the concentration 
corresponding to the signal at CCα + 1.64×the SEI. 
CCα was of 0.02 µg/mL for muscle and liver, 0.04 
µg/mL for kidney and 0.05 µg/mL for skin-fat. CCβ 
was of 0.04 µg/mL for muscle and liver and 0.08 
µg/mL for kidney and skin-fat. 
 
Table 1: Summarizes the validation parameters for each matrix. 
Parameter Accecptance criteria 
Tissue 
Muscle Liver Kidney Skin-fat 
Lineality (r
2
)   > 0.995 0.999 0.997 0.997 0.998 
Precision (CV%) < 15.00 1.02-6.74 0.92-1.05 2.11-2.94 2.15-2.28 
Accuracy (RE %) < 15.00 4.00-9.00 3.00-4.00 2.00-3.00 2.00-3.00 
Recovery (R%) 80.00-120.00 82.56-111.48 90.85-106.10 99.99-120.00 95.04-120 
Limit of quantification 
 
CV % = < 20.00 
ER % = < 20.00 
0,10 µg/mL 
CV % = 7.62 
ER % =   20.00 
0,10 µg/mL 
CV % = 14.42 
ER % = 20.00 
0,10 µg/mL 
CV % = 6.05 
ER % =   20.00 
0,10 µg/mL 
CV % = 14.75 
ER % =   19.00 
CCα (µg/mL) - 0.02 0.02 0.04 0.05 
CCβ (µg/mL) - 0.04 0.04 0.08 0.08 
 
Selection and validation of suitable analytical 
methods must be previously accomplished in drug 
tissue depletion studies for determination of WDTs. 
The HPLC-MS-MS method was selected because of 
its high specificity and accuracy, which were 
considered critical factors for this study. HPLC MS-
MS has been previously used for similar purpose in 
chicken tissues
 
(Soraci et al., 2011b; Pérez et al., 
2011). and studies applying this methodology have 
been also reported by other authors (Dieguez et al., 
2011; Tang and Lai, 2005) 
Solid phase dispersion with silica gel was 
previously used by some authors to determine 
residual concentrations in biological tissues 
(Gutierrez Valencia and García Camacho, 2010; Lei 
et al., 2005) 
The results obtained on the optimization of 
mass spectrometer conditions and optimization of 
chromatographic system, were similar to those 
presented by Li et al (2007) and Dieguez et al 
(2011). The use of a cyano (CN) stationary phase 
markedly improved the retention, when compared 
to a C18. These optimization parameters, in 
addition to the good performance that was achieved 
with water:acetonitrile 80:20 mobile phase, agrees 
with the results described by (Soraci et al, 2011a; 
Soraci et al, 2011b; Dieguez et al, 2011; Pérez et al., 
2011). 
TISSUE DISPOSITION AND WITHDRAWAL TIME OF FOSFOMYCIN IN … 
 
116  J. Anim. Prod. Adv., 2013, 3(4):107-119 
 
Residues Analysis 
The matrix-matched calibration curves of 
muscle, liver, kidney and skin-fat were linear (r > 
0.99) and were used for drug quantification in 
experimental samples. Tables 2 and 3 show the 
average concentration (µg/mL) for each tissue after 
the PO and IM assays, respectively. 
Withdrawal time calculation 
Estimation of withdrawal time (WDT) 
In Table 4, the duration of the WDTs for each 
assay considering a 0.5 µg/mL MRL are shown.  
 
 
Table 2: Fosfomycin average concentrations in muscle, liver, kidney and skin-fat. PO assay. 
 Average concentration (µg/ml) 
PO assay 
24 h 48 h 72 h 96 h 
Muscle 0.20 0.12 < 0.10 < 0.10 
Liver 2.81 0.23 < 0.10 < 0.10 
Kidney 1.97 0.46 < 0.10 < 0.10 
Skin-fat 0.19 < 0.10 < 0.10 < 0.10 
 
Table 3: Fosfomycin average concentrations in muscle, liver, kidney and skin-fat. IM assay. 
 Average concentration (µg/ml) 
IM assay 
24 h 48 h 72 h 96 h 
Muscle 0.32 < 0.10 < 0.10 < 0.10 
Liver 0.33 0.12 < 0.10 < 0.10 
Kidney 0.31 < 0.10 < 0.10 < 0.10 
Skin-fat 0.23 < 0.10 < 0.10 < 0.10 
 
Table 4: Fosfomycin withdrawal time in muscle, liver, kidney and skin-fat, after PO and IM 
administration. 
 Withdrawal time - MRL 0.5 µg/ml 
Muscle Liver Kidney Skin-fat 
PO assay 2.78 2.69 2.95 0.90 
IM assay 1.48 1.73 1.38 1.27 
 
On a previous work we have developed and 
validated the methodology for the determination of 
fosfomycin residual concentrations in broiler 
chicken tissues (muscle, liver and kidney). We have 
also determined the residual concentrations and the 
WDT of this antibiotic on the mentioned matrices, 
after both oral and intramuscular administration 
assays. When compared with our previous work in 
broiler chickens
 
(Pérez et al, 2011), precision value 
(CV %) was higher for pig muscle than for broiler 
chicken muscle (1.02-6.74 % vs. 0.42-4.45 %) and 
lower for liver (0.92-1.05 % vs. 0.82-4.33 %) and 
kidney (2.11-2.94 % vs. 0.23-15.16 %). Accuracy 
(RE %) was higher for pig muscle (4.00-9.00 % vs. 
0.49-2.20 %) and kidney (2.00-3.00 vs. 0.30-1.21 
%) and similar for liver (3.00-4.00 % vs. 0.97-3.76 
%). Recovery was similar between the two species 
for all matrices. For skin-fat all the parameters met 
the acceptance criteria, and they were not analyzed 
in our previous work on broiler chickens. The 
LOQs of 0.1 ppm obtained for all the analyzed 
matrices were low and accurate enough. They were 
lower than the only MRL established for 
fosfomycin residues in animal tissues (0.5 ppm)
 
(Japan Food Chemical Research Foundation) and 
they are in the same range achieved in broiler 
chicken tissues. CCα and CCβ were lower but 
similar to those found in broiler chickens tissues. 
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Overall, the results of the analytical method 
validation indicate that the proposed methodology is 
suitable for the evaluation of fosfomycin tissue 
residues and for the determination of fosfomycin 
concentration depletion in swines, in order to 
establish adequate WDTs. 
In this study, fosfomycin tissue concentration 
and WDTs were determined in pigs after the 
administration of a daily oral dose (30 mg⁄ kg bw 
for five consecutive days), and after an 
intramuscular dose (15 mg/kg bw) considering the 
only established MRL for fosfomycin, 0.5 µg/mL 
(Japan Food Chemical Research Foundation). 
There are no previous works which determine 
fosfomycin tissue concentrations in pigs. Although, 
there are two works that evaluate the residual 
concentrations of Fosfomycin in poultry, one of 
them uses the microbiological assay
 
(Aramayona et 
al, 2005) and the other uses HPLC MS/MS
 
(Pérez et 
al, 2011), as we employed for the determination of 
fosfomycin in pigs.  
The administration of oral calcium fosfomycin 
for five consecutive days at 30 mg/kg in pigs, 
showed low residual levels in swine muscle, liver, 
kidney and skin-fat. In the PO assay, the highest 
WDT was established for kidney and this is 
consistent with our previous studies in broiler’s 
tissues
 
(Pérez et al, 2011). Fosfomycin distribution 
in kidney was higher compared to other tissues 
(liver, muscle and skin-fat, after oral administration 
for five consecutive days), probably due to the fact 
that this organ represents the main route of 
elimination for the systemically available 
fosfomycin dose. Even though, kidney 
concentrations were the highest among the four 
analyzed matrices after the PO assay, the found 
values are not so high, and this may be due to the 
short half-life of the drug and its fast clearance. 
Moreover, there are not big differences between the 
WDT established for muscle and kidney, what 
agrees with our findings in broiler chickens. Such 
low concentrations are associated with the absence 
of Fosfomycin tissue protein binding and the poor 
oral bioavailability of calcium fosfomycin 
formulation in pigs (F: 20%) (Pérez et al, 2013).  
The intramuscularly administration of disodium 
fosfomycin at 15 mg/kg has also showed low 
residual levels in swine tissues, even lower than 
those found with the PO administration. In this case, 
the highest concentrations were found in liver, in 
contrast to our findings in broilers, were the liver 
residual concentrations were the lowest after the IM 
assay. As we have previously reported in broilers
 
(Pérez et al, 2011), Fosfomycin residual 
concentrations are lower after the IM administration 
(disodium fosfomycin), than after the PO 
administration (calcium fosfomycin), and this is due 
to the high hydrosolubility of the disodium salt.  
In all cases, the lowest residual concentrations 
and the short WDT were those found for skin-fat, 
owing to fosfomycin high hydrosolubility. 
Otherwise, the FDA has established that the 
edible tissue from which residues deplete most 
slowly should be considered as the target tissue to 
evaluate the WDT (Ellis, 2004). According to the 
EMEA, target tissues for swine’s are muscle, liver 
kidney and skin-fat. For the calculations of WDTs, 
EMEA (1995) recommends to perform a linear 
regressions analysis of the logarithmic transformed 
concentrations during the tissue depletion phase of 
the drugs and/or their metabolites. Using the model 
of the EMEA, the WDTs of fosfomycin was 
determined as the point at which the upper 95% 
tolerance limit for the residue is less than MRLs 
with 95% confidence. In agreement with
 
the Codex 
Alimentarius Commission (1995), the lengths of the 
WDTs are defined by MRLs of each veterinarian 
drug. In this study, the WDTs of Fosfomycin were 
determined considering the only MRL defined by 
Japan. It is worth pointing out that this MRL was 
established for muscle, liver, kidney and fat from 
cattle, not for pigs. On this regard, based on the 0.5 
µg/mL MRL of Japan, it is important to note that in 
both oral and intramuscular assays, concentrations 
of fosfomycin in muscle, liver, kidney and skin-fat 
were below the MRL after 48 h of fosfomycin food 
withdrawn and of fosfomycin intramuscularly 
administration. After 72 h, the values of the residual 
concentrations of the drug in the analyzed tissues 
were below the 0.1 µg/mL detection limit of our 
validated method. Fosfomycin WDT in muscle was 
among 3-2 days, being of 2.78 days for calcium 
fosfomycin (oral assay) and 1.48 days for disodium 
salt (IM assay). Differences between fosfomycin 
muscle WDTs may be due to the distinct 
formulations and routes of administration. The same 
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applies to periods of withdrawal in liver and kidney 
which are also longer after oral calcium fosfomycin 
consumption in food (2.69 vs. 1.73 days and 2.95 
vs. 1.38 days, respectively). Not significant 
differences were found between the WDTs found 
for skin-fat after the PO assay (0.9 days) and the IM 
assay (1.27).  
In conclusion, according to our results, it is 
possible to suggest that a WDT of 3 days for the PO 
administration, and of 2 days for the IM 
administration, could be assigned as a precautionary 
principle for public health, without a significant 
economic impact for pig producers. 
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